Latest Tax Incentives News

Optiscan Imaging Limited reported a 17.6% revenue decline and a 4.1% increase in net loss for FY25, driven by lower orders and higher R&D spending. The company unveiled two new medical imaging devices as it ramps up commercial efforts.

Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

Resonance Health Limited reported a 29% revenue increase to $11.07 million for FY25 but posted a net loss of $1.73 million, reflecting strategic investments and expansion in clinical trial services.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

Constellation Technologies Limited has reported a 34% revenue increase and a return to profitability in FY25, driven by strong adoption of its IoT-based food safety solutions across multiple sectors. The company is scaling its innovative Callisto platform and hardware offerings to capture broader market opportunities.

Careteq Limited has returned to profitability in FY25, reporting a 5.4% revenue increase and a 171% jump in underlying EBITDA, driven by strategic divestments and acquisitions.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.